Medical Director, Hematology/Oncology Dept, Childrenandapos;s Hospital and Research Center Oakland
Pediatric Hematology & Oncology
Dr. Elliott P. Vichinsky, MD
|
|
Give Review
Elliott P. Vichinsky practices Pediatric Hematology & Oncology. He researched medicine at State University of New York Downstate Medical Center College of Medicine. He received 3 awards: "Regional Top Doctor", "Fellow (FAAP)" and "Super Doctor". Elliott P. Vichinsky is also published. He has 100 publications published. The lastest publication: "Is the Medical Home for Adult Patients with Sickle Cell Disease a Reality or an Illusion?'
Publications
- Is the Medical Home for Adult Patients with Sickle Cell Disease a Reality or an Illusion?
- Emerging therapy in hemoglobinopathies: lessons from the past and optimism for the future.
- Elevated tricuspid regurgitant jet velocity in subgroups of Thalassemia patients: insight into pathophysiology and the effect of splenectomy.
- Efficacy and safety of deferasirox compared with deferoxamine in Sickle cell disease: Two-year results including pharmacokinetics and concomitant hydroxyurea.
- Renal medullary carcinoma in an adolescent with Sickle cell anemia.
- Pregnancy outcomes in women with Thalassemia in North America and the United Kingdom.
- A randomized, placebo-controlled trial of arginine therapy for the treatment of children with Sickle cell disease hospitalized with vaso-occlusive pain episodes.
- Zinc supplementation improves bone density in patients with Thalassemia: a double-blind, randomized, placebo-controlled trial.
- Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention.
- Application of Multiplex Ligation-Dependent Probe Amplification to Screen for ?-Globin Cluster Deletions: Detection of Two Novel Deletions in a Multi Ethnic Population.
- The Palatability and Tolerability of Deferasirox Taken With Different Beverages or Foods.
- Pain in thalassaemia: the effects of age on pain frequency and severity.
- Clinical Manifestations of ?-Thalassemia.
- Human T Cell Lymphotropic Virus Type 1 Infection Among U.S. Thalassemia Patients.
- Increased leucocyte apoptosis in transfused ?-thalassaemia patients.
- Combined chelation therapy with deferasirox and deferoxamine in Thalassemia.
- Treatment of Classic Pantothenate Kinase-Associated Neurodegeneration with Deferiprone and Intrathecal Baclofen.
- The effect of whole body vibration therapy on bone density in patients with Thalassemia: A pilot study.
- Lower alloimmunization rates in pediatric Sickle cell patients on chronic erythrocytapheresis compared to chronic simple transfusions.
- The mediating effects of family functioning on psychosocial outcomes in healthy siblings of children with Sickle cell disease.
- Risks factors and mortality associated with an elevated tricuspid-regurgitant-jet-velocity measured by Doppler-echocardiography in Thalassemia: a Thalassemia Clinical ...
- Reproductive capacity in iron overloaded women with Thalassemia major.
- Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with Sickle cell disease.
- A pilot study of subcutaneous decitabine in β-Thalassemia intermedia.
- Characterization of low bone mass in young patients with Thalassemia by DXA, pQCT and markers of bone turnover.
- The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory Sickle cell anemia patients.
- A pilot study of the short-term use of simvastatin in Sickle cell disease: effects on markers of vascular dysfunction.
- Iron chelation adherence to deferoxamine and deferasirox in Thalassemia.
- Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes.
- A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload.
- Red Cell alloimmunization in a diverse population of transfused patients with thalassaemia.
- Renal dysfunction in patients with thalassaemia.
- Effect of transfusion therapy on transcranial Doppler ultrasonography velocities in children with Sickle cell disease.
- Heterogeneity of hemoglobin H Disease in childhood.
- Transfusion and chelation practices in Sickle cell disease: a regional perspective.
- Approaches to transfusion therapy and iron overload in patients with Sickle cell disease: results of an international survey.
- Quality of life in Thalassemia: a comparison of SF-36 results from the Thalassemia longitudinal cohort to reported literature and the US norms.
- Novel influenza A (H1N1) viral infection in pediatric patients with Sickle-cell disease.
- HbE/beta-Thalassemia: basis of marked clinical diversity.
- Chart Card: feasibility of a tool for improving emergency department care in Sickle cell disease.
- Pulmonary hypertension in hemolytic anemias.
- Relationship between chronic transfusion therapy and body composition in subjects with Thalassemia.
- Education and employment status of children and adults with Thalassemia in North America.
- Complexity of alpha Thalassemia: growing health problem with new approaches to screening, diagnosis, and therapy.
- Fertility potential in Thalassemia major women: current findings and future diagnostic tools.
- Pulmonary hypertension and NO in Sickle cell.
- Pulmonary hypertension in Thalassemia.
- Preface to Cooley's Anemia: Ninth Symposium.
- Health-related quality of life in children with Sickle cell disease: a report from the Comprehensive Sickle Cell Centers Clinical Trial Consortium.
- Application of an expanded multiplex genotyping assay for the simultaneous detection of Hemoglobin Constant Spring and common deletional alpha-Thalassemia mutations.
- The risks and benefits of long-term use of hydroxyurea in Sickle cell anemia: A 17.5 year follow-up.
- Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with Sickle cell anemia.
- Pain as an emergent issue in Thalassemia.
- Assessment of cardiac iron by MRI susceptometry and R2* in patients with Thalassemia.
- Elevated exhaled carbon monoxide concentration in hemoglobinopathies and its relation to red blood Cell transfusion therapy.
- Severe Sickle cell disease--pathophysiology and therapy.
- Hemoglobin Hakkari: an autosomal dominant form of beta Thalassemia with inclusion bodies arising from de novo mutation in exon 2 of beta globin gene.
- Serum ferritin level changes in children with Sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury.
- Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload.
- Low dose, oral epsilon aminocaproic acid for renal papillary necrosis and massive hemorrhage in hemoglobin SC Disease.
- Iron metabolism and iron chelation in Sickle cell disease.
- Hemoglobin H-constant spring in North America: an alpha Thalassemia with frequent complications.
- Climatic and geographic temporal patterns of pain in the Multicenter Study of Hydroxyurea.
- Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America.
- HLA type and risk of alloimmunization in Sickle cell disease.
- Bone Disease in thalassemia: a frequent and still unresolved problem.
- Newborn screening for hemoglobinopathies in California.
- An expanded Transactional Stress and Coping Model for siblings of children with Sickle cell disease: family functioning and sibling coping, self-efficacy and perceived...
- Alpha Thalassemia major--new mutations, intrauterine management, and outcomes.
- Pulmonary complications of Sickle cell disease.
- Hemoglobinopathies.
- Psychosocial and behavioral outcomes in children with Sickle cell disease and their healthy siblings.
- Hydroxycarbamide-induced changes in E/beta thalassemia red blood Cells.
- Disparity in the management of iron overload between patients with Sickle cell disease and thalassemia who received transfusions.
- Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with Thalassemia.
- Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in Sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomize...
- Detection and assessment of stroke in patients with Sickle cell disease: neuropsychological functioning and magnetic resonance imaging.
- Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with Sickle cell disease and thalassemia.
- Oral iron chelators and the treatment of iron overload in pediatric patients with chronic anemia.
- Inflammation and oxidant-stress in beta-Thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL6...
- Clinical application of deferasirox: practical patient management.
- Advances in clinical research in Sickle cell disease.
- Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with Sickle cell anemia.
- Gender differences in smoking and cessation behaviors among young adults after implementation of local comprehensive tobacco control.
- Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study.
- Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in Sickle cell disease.
- Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and c...
- Clinical differences between children and adults with pulmonary hypertension and Sickle cell disease.
- Transfusional iron burden and liver toxicity after bone marrow transplantation for Acute myelogenous leukemia and hemoglobinopathies.
- Hemoglobin e syndromes.
- Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-Thalassemia.
- Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and Sickle cell ...
- Iron homeostasis during transfusional iron overload in beta-thalassemia and Sickle cell disease: changes in iron regulatory protein, hepcidin, and ferritin expression.
- Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator.
- Morbidity and mortality in chronically transfused subjects with thalassemia and Sickle cell disease: A report from the multi-center study of iron overload.
- A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in Sickle cell disease.
- Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in Sickle cell disease. Results of a multicenter study at a...
- Bone mineral density in children with Sickle cell anemia.
- Caregiving time in Sickle cell disease: psychological effects in maternal caregivers.
Schools
SUNY Downstate Medical Center College Of Medicine
University Hospital Chldns Orth Hospital Med
Chldns Orth Hospital Med C
University of Washington
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Lymphoma
- Osteosarcoma
- View All
Doctors Specialties
- Pediatric Hematology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
- Fellow (FAAP)
- Super Doctor
Education
-
University of Washington -
State University of New York Downstate Medical Center College of Medicine
Hospital
-
Alta Bates Summit Medical Center - Summit Campus -
UCSF Medical Center -
Alta Bates Summit Medical Center -
John Muir Medical Center, Walnut Creek
Helpful Reviews
Similar Doctors
|
|
Dr. Julian R. Davis Jr., MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James H. Feusner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carla B. Golden, MD
This Doctor is OpenDoctor Recommended.
|